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Objectives: Morbidity is an important risk factor for mortality and a variety of morbidity measures have
been developed to predict patients’ health outcomes. The objective of this systematic review was to
compare the capacity of morbidity measures in predicting mortality among inpatients admitted to in-
ternal medicine, geriatric, or all hospital wards.
Design: A systematic literature search was conducted from inception to March 6, 2019 using 4 databases:
Medline, Embase, Cochrane, and CINAHL. Articles were included if morbidity measures were used to
predict mortality (registration CRD42019126674).
Setting and Participants: Inpatients with a mean or median age 65 years.
Measurements: Morbidity measures predicting mortality.
Results: Of the 12,800 articles retrieved from the databases, a total of 34 articles were included reporting
on inpatients admitted to internal medicine, geriatric, or all hospital wards. The Charlson Comorbidity
Index (CCI) was reported most frequently and a higher CCI score was associated with greater mortality
risk, primarily at longer follow-up periods. Articles comparing morbidity measures revealed that the
Geriatric Index of Comorbidity was better predicting mortality risk than the CCI, Cumulative Illness
Rating Scale, Index of Coexistent Disease, and disease count.
Conclusions and Implications: Higher morbidity measure scores are better in predicting mortality at
longer follow-up period. The Geriatric Index of Comorbidity was best in predicting mortality and should
be used more often in clinical practice to assist clinical decision making.
 2019 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Chronologic age is a major risk factor for the development and prognostic implications. The Charlson Comorbidity Index (CCI), Elixhauser
accumulation of age-related diseases.1 Multimorbidity, defined as the
concurrent presence of 2 ormore diseases, is prevalent in 62% of adults
aged 65 to 74 years and 81.5% of those aged 85 years or older living in
major western countries.2 The clinical relevance of multimorbidity and
comorbidities, defined as conditions that coexist with a disease of
interest,3 is the synergistic effect of co-occurring diseases in prediction
of poor health outcomes.4e7 These poor health outcomes include
hospitalization, readmission, functional decline, and mortality.6
A number of measures have been developed to characterize the
quantity and severity of individuals’ disease burden and associatedity of Melbourne to Professor
hD, Department of Medicine
e Hospital, The University of
ier).
te and Long-Term Care Medicine.Comorbidity Index, and Cumulative Illness Rating Scale (CIRS) are exam-
ples that are being frequently used in clinical settings8e10 to predict both
short- and long-termmortality.11 Thesemeasuresdiffer in thenumberand
type of included diseases and their assigned weightings.6,12,13 Conse-
quently, the appropriateness and predictive capacity of specific measures
varies according to the clinical profile of the patient cohorts.
The aim of this systematic review is to compare the capacity of
morbidity measures for the prediction of mortality among inpatients.
Methods
Search Strategy
A systematic literature searchwas performed in accordancewith the
Preferred Reporting Items for Systematic Reviews and Meta-analysis
(PRISMA) guidelines and registered on PROSPERO (registration
numberCRD42019126674). The searchwas conducted from inception to
C.H. Soh et al. / JAMDA 21 (2020) 462e468 463March6, 2019, using4 electronic databases: (1)MEDLINE(R), (2) Embase
Classic þ Embase, (3) Cochrane Central Register of Controlled Trials via
the Ovid platform, and (4) CINAHL complete. To avoid selection bias of
comorbidity scores, our search terms included the keywords "comor-
bidity" or "multimorbidity" adjacent to "index," "indices," "measure,"
"rating," or "scoring." Known comorbidity scores or their abbreviation
were also included in our search strategy to reduce the possibility of
missing articles. Therefore, both widely used and new (unknown)
comorbidities scores were included (Supplementary Material 1). Titles
and abstracts of articles were screened independently by 2 authors (C.S.
and S.H.). Conflicts were resolved by a third reviewer (J.S. or A.M.).
Study Selection
Longitudinal studies that reported the association between
morbidity measures and mortality in inpatients were included.
Exclusion criteria were (1) mean or median age of the cohort below
65 years, (2) cross-sectional data analyses, (3) language other than
English, and (4) American Society of Anesthesiologist (ASA) physical
status classification status being the only measure used. The ASA
classification was excluded because of its subjective assessment of
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Fig. 1. PRISMA flowchart forArticles were divided into 7 subgroups of inpatients: (1) cancer; (2)
musculoskeletal conditions; (3) respiratory diseases; (4) cardiovas-
cular and metabolic diseases; (5) other diseases; (6) surgical in-
terventions; and (7) inpatient groups being admitted to internal
medicine wards, geriatric wards, or all hospital wards without focus
on a specific diseases. This review solely describes articles describing
the results of the last group (7).
Data Extraction and Quality Assessment
For each included article, information relating to study design,
population demographics, morbiditymeasures, baseline score, follow-
up duration, and mortality were extracted in a standardized way by 2
independent authors (C.S. and S.H.). The quality assessment was
performed using an adapted Newcastle-Ottawa Scale (NOS)
(Supplementary Material 2). Disagreement in data extraction was
resolved by a third reviewer (J.S. and A.M.).
Data Analysis
The predictive ability of each morbidity measure was reported as
the area under the curve (AUC) in a receiver operating characteristicRecords excluded 
(n=6022) 
Full-text articles excluded (n=753) 
Mean/median age <65 years, n=413 
Predictor/outcome irrelevant, n=115 
Not inpatients, n=76 
ASA physical status, n=43 
Conference abstract, n=32 
Full text not available, n=74 




Cardiovascular and metabolism, 
n=81 
Surgical intervention, n=103 
Other, n=89 
the selection of articles.
Table 1
Characteristics of Included Studies





Arminanzas (2013)16 ES P 18 78.0  14.0 539 48.8
Barba (2011)17 ES R* 65 NG 1,135,423 50.1
Beglinger (2015)18 CH P 18 Median: 81 1278 61.2
Buurman (2011)19 NL P 65 78.2  7.8 639 53.8
Conde-Martel (2012)20 ES P 90 92.8  2.6 124 63.7
Dias (2015)21 PT P 65 80.6  7.8 100 42
Duque (2011)22 PT P No 67.1  19.3 288 NG
Fabbian (2017)23 IT R* No 72.7  16.3 75,586 53.4
Frenkel (2014)24 NL P 65 77.8  7.9 1313 54.2
Helvik (2013)25 NO P 65 80.7  7.4 484 50.2
Hernandez-Luis (2018)26 ES P 60 76.6 298 50
Incalzi (1997)27 IT P NG 78.7  5.9 370 55.1
Iwata (2006)28 JP P 85 88.7  2.4 403 63.8
Olsson (2005)29 SE P No 68.8  7.1 865 50.9
Salvi (2008)30 IT P 65 76.7  7.0 387 39.8
Tal (2011)31 IL R* 65 81.5 1509 62
Acute Geriatric Wards
Beloosesky (2011)32 IL P 65 81.0  7.3 212 61.8
Bien (2015)33 PL R NG 77.9  6.8 478 71.5
Martinez-Velilla (2014)34 ES P 75 85.4  5.4 122 56.6
Martinez-Velilla (2013)35 ES P 75 85.4  5.4 122 56.6
Ritt (2017)36 DE P 65 82.9  6.4 307 67.4
Zekry (2009)37 CH P 75 85.3  6.7 444 74.1
Zekry (2010)38 CH P 75 85.3  6.7 444 74.1
Zekry (2010)39 CH P 75 85.3  6.7 444 74.1
Zekry (2011)40 CH P 75 85.3  6.7 444 74.1
Zekry (2012)41 CH P 75 85.3  6.7 444 74.1
Zekry (2012)42 CH P 75 85.3  6.7 444 74.1
Subacute Geriatric Wards
Bellelli (2008)43 IT P 65 76.6  10.5 1323 71.8
Bernard (2016)44 AU P 65 81.9  8.0 306 58.2
Rozzini (2002)45 IT P NG 78.9  7.4 493 70.8
Rozzini (2005)46 IT P 60 78.3  8.5 950 69.3
All admitted inpatients
D’Hoore (1993)47 CA R* No Median: 66 62,456 40.6
Moore (2017)48 US R* 18 NG 21,911,643 53.3
Quan (2011)49 CA R* 18 NG 55,929 64.6
AU, Australia; CA, Canada; CH, Switzerland; Ctry, country; DE, Germany; ES, Spain; IL, Israel; IT, Italy; JP, Japan; NG, not given; NL, the Netherlands NO, Norway; P, prospective;
R, retrospective; PL, Poland. PT, Portugal; R, retrospective; SE, Sweden; US, United States of America.
Age was stated in mean  SD year unless stated otherwise.
*Administrative data used.
C.H. Soh et al. / JAMDA 21 (2020) 462e468464curve, relative risk (RR), odds ratio (OR), or hazard ratio (HR)
depending on the statistical analysis used in each article. Compre-
hensive Meta-Analysis (CMA) was used to visualize the association of
morbidity measure and mortality (v 3.3; Biostat Inc, Englewood, NK).
Publication bias was assessed via a funnel plot using CMA and tested
by the Egger regression.15
Results
The literature search revealed a total of 12,800 articles. After
removing 5466 duplicates, 7334 articles were screened based on titles
and abstracts. Of these, 6022 articles were excluded, leaving 1312
articles for full-text screening. A total of 525 articles focused on
disease-specific patient populations, leaving 34 articles reporting on
patients admitted to internal medicine wards, geriatric wards, or the
entire hospital to be included (Figure 1). Risk of bias for every included
article were assessed and reported in Supplementary Table 1.
Table 1 summarizes the characteristics of each study. A total of
23,256,611 inpatients (mean age 73.82 years, 53.1% female) were
included in 27 prospective and 7 retrospective cohort studies.
Among the 7 retrospective studies, 6 studies used administrative
data (n ¼ 23,242,546 inpatients). Sixteen articles described the asso-
ciation between morbidity measures and mortality in patients
admitted to internal medicine wards,11 articles in patients admitted toacute geriatric wards, 4 articles in patients admitted to subacute
geriatric wards, and 3 articles included entire hospital inpatients. The
Charlson Comorbidity Index (CCI) was used most frequently (26/34
articles) in predicting mortality, followed by Cumulative Illness Rating
Scale (CIRS) (8/34 articles) and Geriatric Index of Comorbidity (GIC) (8/
34 articles). Other morbidity measures including Chronic Disease Score
(CDS) and Index of Coexistent Disease (ICED) were reported in 3 and 6
articles respectively. The median follow-up period was 12 months.
Table 2 shows the association of morbidity measures andmortality
according to follow-up period. Overall, higher CCI, CIRS, GIC, and ICED
scores predicted at a longer follow-up period, which is summarized in
Supplementary Table 2.
Four out of 7 articles reported that CCI score, per 1-point
increase, was significantly associated with in-hospital
mortality.17,22,31,37,38,44,49 For postdischarge mortality, higher
CCI scores were associated with greater
mortality.16,18e20,24e26,28,29,32,34,35,37,39,43,43,46,47,49,33 Figure 2 visual-
izes the association of a higher CCI scores with increasedmortality risk
at a longer follow-up period.
CIRS was not predictive for in-hospital mortality,38 but a CIRS score
of 15 points and higher was predictive for post-discharge mortal-
ity.34,35,39,43 All 3 articles reported that CIRS, as per 1 point increase, is
significantly associated with postdischarge mortality.30,32,36 Of the
study that reported GIC and its association with in-hospital mortality,
Table 2
Morbidity Measures and its Association With Mortality According to Morbidity
Measure and Follow-Up Period
Author (Y) FU Result P
CCI
Barba (2011)17 IH OR 1.21 (1.16e1.26) Sig.
Bernard (2016)44 IH Higher CCI score groups did not have a
significantly greater proportion of deathsy
Duque (2011)22 IH OR 1.16 (1.01e1.31) Sig.
AUC 0.59 (0.49e0.69) NS
Quan (2011)49 IH AUC 0.88 Sig.
Tal (2011)31 IH OR 1.18 (0.98e1.41) NS
Zekry (2009)37 IH OR 3.93 (1.86e8.29) Sig.
Zekry (2010)38 IH OR 0e6: Ref -
7e14: 1.15 (0.96e1.37) NS
Olsson (2005)29 3 d HR 0.87 (0.74e1.03) .11
7 d HR 0.91 (0.79e1.05) .19
30 d HR 1.02 (0.92e1.13) .71
Arminanzas
(2013)16
1 mo AUC 0.65 Sig.
Sens. 0.60 (0.48e0.72)
Spec. 0.68 (0.63e0.72)
OR 0e1: Ref -
2: 1.92 (0.80e4.61) NS
>2: 3.54 (1.70e7.36) Sig.
Beglinger (2015)18 1 mo OR* 1.26 (1.15e1.37) Sig.
AUC 0.67 (0.61e0.74) Sig.
Quan (2011)49 1 mo AUC 0.88 Sig.
Olsson (2005)29 90 d HR 1.07 (0.98e1.17) .1
Beloosesky (2011)32 3 mo OR 2.06 (1.40e3.02) Sig.
Frenkel (2014)24 3 mo AUC 0.66 Sig.
OR 0: Ref -
1e2: 0.7 (0.3e1.3) .24
3e4: 1.1 (0.6e2.2) .69
5: 3.3 (2.0e7.2) Sig.
Rozzini (2005)46 6 mo RR* 2.5 (1.3e4.8) Sig.
Bellelli (2008)43 12 mo OR* 0e2: Ref -
3e4: 2.4 (1.2e12.0) Sig.
5: 6.0 (3.0e11.8) Sig.
Buurman (2011)19 12 mo HR 1.19 (1.13e1.26) Sig.
D’Hoore (1993)47 12 mo OR 0: Ref -
1e2: 0.67 (0.64e0.71) NS
3e4: 1.17 (1.13e1.21) Sig.
5e6: 1.68 (1.62e1.73) Sig.
7: 2.15 (2.07e2.22) Sig.
Dias (2015)21 12 mo Actual mortality is 3 times lower than the
predicted mortality (in %)y
Iwata (2006)28 12 mo HR 0: Ref -
1: 3.79 (0.85e16.99) NS
>2: 4.71 (1.09e20.42) .04
Frenkel (2014)24 12 mo AUC 0.7 Sig.
OR 0: Ref -
1e2: 1.2 (0.6e2.2) .63
3e4: 2.2 (1.2e4.1) Sig.
5: 8.1 (4.5e14.6) Sig.
Martinez-Velilla
(2013)35
12 mo AUC 0.62 (0.52e0.72) Sig.
OR 1: Ref -
2: 2.86 (1.05e7.81) Sig.
3: 2.73 (0.91e8.13) NS
4: 2.82 (1.01e7.90) Sig.
Olsson (2005)29 12 mo HR 1.16 (1.09e1.23) Sig.
Quan (2011)49 12 mo AUC 0.9 Sig.
Zekry (2012)41 12 mo OR* 0e3: Ref -
4: 1.68 (0.88e3.21) Sig.
5e6: 1.74 (0.92e3.28) NS
7e14: 2.49 (1.34e4.60) Sig.
Hernandez-Luiz
(2018)26
24 mo HR 0e2: Ref -
3: 1.68 (1.15e2.45) Sig.
Helvik (2013)25 36 mo HR 1.73 (1.09e2.74) Sig.
Olsson (2005)29 36 mo HR 1.18 (1.13e1.24) Sig.
56 mo HR 1.20 (1.15e1.25) Sig.
Frenkel (2014)24 60 mo AUC 0.73 Sig.
OR 0: Ref -
1e2: 4.4 (1.4e14.4) .01
3e4: 6.3 (1.9e21.2) Sig.
5: 39.9 (9.3e170.9) Sig.
(continued)
Table 2 (continued )
Author (Y) FU Result P
Martinez-Velilla
(2014)34
60 mo AUC 0.64 (0.53e0.75) Sig.
OR 1: Ref -
2: 1.92 (0.66e5.61) NS
3: 2.30 (0.67e7.90) NS
4: 4.03 (1.06e15.31) Sig.
Zekry (2010)39 60 mo HR* 0e3: Ref -
4: 1.14 (0.81e1.62) NS
5e6: 1.46 (1.05e2.04) Sig.
7e14: 2.49 (1.23e2.32) Sig.
Bien (2015)33 65 mo HR 1.25 (1.17e1.33) Sig.
CIRS
Zekry (2010)38 IH OR 0e18: Ref -
19e30: 1.21 (0.20e7.14) NS
Beloosesky (2011)32 3 mo OR 1.50 (1.22e1.84) Sig.
Martinez-Velilla
(2013)35
12 mo AUC 0.54 (0.44e0.65) NS
OR 1: Ref -
2: 1.26 (0.44e3.60) NS
3: 0.77 (0.27e2.20) NS
4: 1.85 (0.62e5.50) NS
Ritt (2017)36 12 mo AUC 0.77 (0.71e0.91) Sig.
HR 1.76 (1.49e2.09) Sig.
Zekry (2012)42 12 mo OR* 0e11: Ref -
12e14: 1.61 (0.71e3.62) .25
15e18: 3.70 (1.82e7.53) Sig.
19e30: 6.33 (3.17e12.65) Sig.
Salvi (2008)30 18 mo HR 1.08 (1.03e1.14) .01
Martinez-Velilla
(2014)34
60 mo AUC 0.54 (0.42e0.66) NS
OR 1: Ref -
2: 1.23 (0.40e3.78) NS
3: 0.97 (0.34e2.80) NS
4: 2.25 (0.60e8.46) NS
Zekry (2010)39 60 mo HR* 0e11: Ref -
12e14: 1.15 (0.79e1.69) NS
15e18: 2.01 (1.42e2.84) Sig.
19e30: 3.17 (2.24e4.48) Sig.
GIC
Zekry (2010)38 IH OR 1e2: Ref -
3: 3.68 (3.01e6.26) Sig.
4: 4.34 (3.92e9.52) Sig.
Martinez-Velilla
(2013)35
12 mo AUC 0.69 (0.59e0.79) Sig.
OR 1: Ref -
2: 0.90 (0.23e3.51) NS
3: 1.85 (0.47e7.32) NS
4: 5.03 (1.40e18.1) Sig.
Rozzini (2002)45 12 mo RR 2.3 (1.7e3.1) Sig.
Zekry (2012)41 12 mo OR* 1e2: Ref -
3: 8.15 (1.13e58.91) Sig.
4: 27.6 (3.80e200.51) Sig.
Martinez-Velilla
(2014)34
60 mo AUC 0.66 (0.56e0.76) Sig.
OR 1: Ref -
2: 0.50 (0.15e1.67) NS
3: 1.04 (0.27e4.01) NS
4: 4.62 (0.96e22.09) NS
Zekry (2010)39 60 mo HR* 1e2: Ref -
3: 1.63 (1.00e2.66) Sig.
4: 3.85 (2.29e6.47) Sig.
Zekry (2011)40 60 mo HR 1e2: Ref -
3: 1.43 (0.86e2.39) NS
4: 2.74 (1.58e4.89) Sig.
Zekry (2012)41 60 mo HR 1e2: Ref -
3: 1.24 (0.75e2.06) NS
4: 2.45 (1.40e4.28) Sig.
ICED
Zekry (2010)38 IH OR 1e3: Ref -
4: 1.36 (1.01e1.83) Sig.
Martinez-Velilla
(2013)35
12 mo AUC 0.58 (0.47e0.68) NS
OR 1: Ref -
2: 0.98 (0.29e3.32) NS
3: 1.41 (0.51e3.84) NS
4: 2.28 (0.79e6.61) NS
Rozzini (2002)45 12 mo RR 1.0 (0.9e1.2) NS
Zekry (2012)42 12 mo OR* 1e3: Ref -
4: 2.58 (1.34e4.96) Sig.
(continued on next page)
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Table 2 (continued )
Author (Y) FU Result P
Martinez-Velilla
(2014)34
60 mo AUC 0.56 (0.45e0.67) NS
OR 1: Ref -
2: 0.70 (0.21e2.34) NS
3: 0.75 (0.26e2.12) NS
4: 2.17 (0.58e8.20) NS
Zekry (2010)39 60 mo HR* 1e3: Ref -
4: 1.71 (1.23e2.37) Sig.
CDS
Zekry (2010)38 IH OR* 0e3: Ref -
4e6: 0.62 (0.14e2.64) NS
7-8: 1.60 (0.49e5.21) NS
9e15: 2.13 (0.67e6.70) NS
Zekry (2012)42 12 mo OR* 0e3: Ref -
4e6: 1.04 (0.59e1.82) .89
7e8: 1.20 (0.68e2.16) .44
9e15: 1.24 (0.71e2.13) .55
Zekry (2010)39 60 mo HR* 0e3: Ref -
4e6: 1.12 (0.80e1.57) NS
7e8: 1.16 (0.83e1.64) NS
9e15: 1.38 (0.98e1.94) NS
DC
Moore (2017)48 IH AUC 0.73 (0.73e0.73) Sig.
Martinez-Velilla
(2013)35
12 mo AUC 0.61 (0.50e0.71) Sig.
OR 1: Ref -
2: 0.81 (0.24e2.72) NS
3: 2.01 (0.77e5.26) NS
4: 1.81 (0.66e4.96) NS
Rozzini (2002)45 12 mo RR 0.8 (0.8e1.1) NS
Martinez-Velilla
(2014)34
60 mo AUC 0.58 (0.45e0.70) NS
OR 1: Ref -
2: 5.76 (1.17e28.24) Sig.
3: 2.38 (0.84e6.75) NS
4: 1.92 (0.66e5.56) NS
KFI
Zekry (2010)38 IH OR 0e2: Ref -
6e16: 1.71 (0.28e10.50) NS
Zekry (2012)42 12 mo OR* 0e2: Ref -
3e4: 1.54 (0.84e2.84) .17
5: 2.47 (1.22e4.99) Sig.
6e16: 3.45 (1.92e6.19) Sig.
Zekry (2010)39 60 mo HR* 0e2: Ref -
3e4: 1.36 (0.98e1.89) NS
5: 2.04 (1.36e3.05) Sig.
6e16: 2.46 (1.75e3.45) Sig.
EI
Fabbian (2017)23 IH AUCz 0.72 (0.71e0.73) Sig.
IH AUC 0.66 (0.65e0.66) Sig.
Moore (2017)48 IH AUC 0.80 (0.80e0.80) Sig.
ICI
Incalzi (1997)27 IH AUCz 0.57 Sig.
Sens.z 0.71
Spec.z 0.69
ORz 1.77 (1.15e2.72) Sig.
IH AUC 0.46 NS
Sens. 0.64
Spec. 0.64
OR 1.58 (1.03e2.43) Sig.
AUC, area under the receiver operating characteristic curve; CDS, chronic disease
score; d, days in follow-up period; DC, diagnosis count; EI, Elixhauser Comorbidity
Index; FU, follow-up; KFI, Kaplan-Feinstein Index; HR, hazard ratio; ICI, Incalzi
Comorbidity Index; IH, in-hospital; MM, morbidity measure; mo, months in follow-
up period; NG, not given; NS, not significant; OR, odds ratio; Ref, reference; RR,
relative risk; Sens, sensitivity; Sig., significant; Spec, specificity.
Statistical results were stated as morbidity score: statistical result (95% confidence
interval) or statistical result per 1-point increase and adjusted for at least age and
sex unless stated otherwise.
*Univariate analysis.
yStatistical report and result were not given.
zAge modified morbidity measure.
C.H. Soh et al. / JAMDA 21 (2020) 462e468466a GIC score of 3 or higher was reported significant.38 For postdischarge
mortality, a greater proportion of articles reported that a higher GIC
score and longer follow-up period is significantly
predictive.34,35,39,42,43,45Among the 6 articles reporting ICED, 1 article reported an insig-
nificant association with in-hospital mortality. Two out of the 5 arti-
cles reporting postdischarge mortality showed that only ICED score of
4 was significantly associated with mortality.34,35,38,39,43,45 All 3
studies that reported CDS showed that all CDS score did not associate
with in-hospital, 12-month, or 60-month mortality risk.38,39,43
Two studies compared the capacity of morbidity measures pre-
dicting mortality and GIC was shown to have the highest AUC among
CCI, ICED, CIRS, and disease count (Table 2).34,35 By including age in the
scoring system, 2 studies showed that a modified morbidity measure
had a higher AUC predicting mortality than the original morbidity
measure itself (Table 2).23,27
The visual inspection of the funnel plot and the Egger regression
test indicated insignificant publication bias (P value ¼ .134)
(Supplementary Figure 1).
Discussion
Higher CCI, CIRS, and GIC morbidity scores predict greater post-
discharge mortality risk in patients admitted to internal medicine
wards, geriatric wards, and the overall hospital wards. The predictive
capacity of morbidity scores is higher at longer follow-up periods.
Among the studies comparing the capacity of morbidity measure, GIC
was shown to be better in predicting mortality than CCI, CIRS, ICED,
and disease count among inpatients.
As the most frequently used morbidity measure, the CCI signifi-
cantly predicted postdischarge mortality among patients with a
higher predictive capacity at longer follow-up periods. CCI is not
predictive for in-hospital mortality, and this may be due to the fact
that morbidities and their corresponding weight listed in CCI was
initially assigned and validated in predicting 10-years mortality.8
CIRS is a comprehensive measure that comprised all physiological
systems with clear ranking severity, and it was shown to be predictive
for postdischarge mortality. However, CIRS was shown to be unable to
predict in-hospital mortality,38 and this is possibly because of the
inclusion of specific diseases such as psychiatric morbidities. They are
highly prevalent in older inpatients50,51 but generally have insignifi-
cant association with in-hospital mortality,52 which in turn results in
the inability of CIRS in predicting in-hospital mortality.
Among all morbidity measures, GIC was shown to have the
greatest predictive capacity with mortality in comparative studies.
Although most morbidity measures focus on weighing the severity of
eachmorbidity, GIC is different as it incorporates both the number and
severity of diseases, hence, the ability to capture the co-occurrence of
diseases and corresponding severity.
Among all morbidity measures, ICED is the only one incorporating
patients’ physical impairment as one of the components.53 ICED was
developed in patients undergoing total hip replacement to predict
patients’ recovery and postoperative complications.54 Hence, by
considering physical impairment as a morbidity, it was mainly used to
predict patients’ physical function and disability.38,55 However, it was
not developed nor validated for the purpose of predicting mortality,
resulting in its inability to reflect those who are at higher risk.
CDS was shown to be unable to predict in-hospital, 12-month, or
60-month mortality. CDS is a morbidity measure that incorporates
drugs dispensed as surrogate markers for morbidity instead of clinical
diagnoses.56,57 The poor performance of CDS in predicting mortality
may not only be because it was designed initially to predict hospi-
talizaion, but may also be due to the addition of new drug classes since
the development of the CDS in 1992, and the possibility of morbidity
that is not treated with medication.
Morbidity measures taking the age of the patients into account
were shown to be better in predicting mortality.23,27 Most of the
chronic morbidities were age-related, caused by the progressive
deterioration in the function of organs.58 Chronologic age was also
Fig. 2. Predictive capacity of CCI scores on mortality stratified by morbidity score and follow-up period.
C.H. Soh et al. / JAMDA 21 (2020) 462e468 467shown to be a significant predictor of mortality, hence, including age
in the model is conceivable.59
To the best of our knowledge, this is the first systematic review that
compares all morbidity measures that were used in a general medical
hospital setting regardless of administrative or clinical data. Admin-
istrative data provide a large sample size, however, incomplete or
incorrect coding in addition to temporal changes in coding practices
may impact the sensitivity and specificity of the risk models. On the
other hand, clinical data are more likely to detect historical or
asymptomatic morbidities, such as prior myocardial infarction and
hyperlipidemia.60,61 A meta-analysis was not performed due to the
differences in statistical analysis, follow-up period, and cut-off value
chosen for each morbidity measure. Further research is required to
determine the predictive capacity of each morbidity measure within
specific disease population as it is important to determine if the
finding from this review is valid and consistent throughout the study
population with different index diseases.Conclusions and Implications
The CCI is the most frequently used morbidity measure, and it is
better predicting mortality at higher scores and longer follow-up
period. The GIC has better predictive capacity than CCI, CIRS, ICED,
and disease count in clinical settings. Overall, a weighted comorbidity
index is useful in reflecting inpatients’ health status and GIC should be
used more often as a prognostic tool to reflect high-risk patients.Acknowledgments
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heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
966
14 ("comprehensive prognostic index" or (CPI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
67
15 ("american society of anesthesiologists physical status" or (ASA and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp.
[mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
4985
16 ("adult comorbidity evaluation 27" or (ACE-27 and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
318
17 (“simplified comorbidity index” or (SCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
566
18 ("multipurpose australian comorbidity scoring system" or (MACSS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp.
[mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
3
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19 ("national cancer institute comorbidity index" or (NCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title,
abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
358
20 ("functional comorbidity index" or (FCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms]
146
21 ("geriatric index of comorbidity" or (GIC and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
33
22 (mortality or death).mp. [mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
2166576
23 ("Activit* of Daily Living" or "Activit* of Daily Life" or "ADL" or "iADL" or "functional decline" or (disabil* adj3 function)).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
51124
24 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 34500
25 22 OR 23 2211660
26 24 AND 25 15140
27 Limit 26 to aged <65þ years> 7231
28 (elderly or ((old or older or aged) adj (person* or patient* or people or male or female or males or females or men or women or individual* or
population)) or elder or geriatric*).mp. [mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
924670
29 26 AND 28 4494
30 27 OR 29 8024
31 Limit 30 to conference abstract status 2348
32 30 NOT 31 5677
33 Limit 32 to English language 5467
(3) Cochrane
1 ((comorbid* or "co morbid*" or multimorbid* or "multi morbid*") adj3 (index* or indice* or measure* or rating* or scale* or score or scoring)).mp.
[mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
1289
2 (“Cumulative Illness Rating Scale" or (CIRS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
68
3 (“Kaplan Feinstein index” or (KFI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
0
4 (“charlson comorbidity index" or "Charlson index" or (CCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title,
abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
544
5 (“Deyo Charlson comorbidity index” or “Deyo charlson index” or (DCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) or (DCCI
and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
8
6 (“Charlson deyo comorbidity index” or “Charlson deyo index” or (CDI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) or
(CDCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
31
7 (“aggregated diagnosis group” or (ADG and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
0
8 (“adjusted clinical group” or (ACG and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
3
9 (“chronic disease score” or (CDS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms]
15
10 (“index of coexistent disease” or (ICED and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
5
11 ("satariano index" or (SI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
773
12 ("total illness burden index" or (TIBI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
0
13 ("Elixhauser comorbidity index" or "Elixhauser index" or (EI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) or (ECI and
(comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
35
14 ("comprehensive prognostic index" or (CPI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
0
C.H. Soh et al. / JAMDA 21 (2020) 462e468468.e3
15 ("american society of anesthesiologists physical status" or (ASA and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp.
[mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
776
16 ("adult comorbidity evaluation 27" or (ACE-27 and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
19
17 (“simplified comorbidity index” or (SCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
28
18 ("multipurpose australian comorbidity scoring system" or (MACSS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp.
[mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
0
19 ("national cancer institute comorbidity index" or (NCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title,
abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
25
20 ("functional comorbidity index" or (FCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
10
21 ("geriatric index of comorbidity" or (GIC and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))).mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier, synonyms]
2
22 (mortality or death).mp. [mp¼title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
77551
23 ("Activit* of Daily Living" or "Activit* of Daily Life" or "ADL" or "iADL" or "functional decline" or (disabil* adj3 function)).mp. [mp¼title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms]
9161
24 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 2886
25 22 OR 23 86054
26 24 AND 25 697
27 Limit 26 to English language 668
(4) Cinahl
S1 (comorbid* or "co morbid*" or multimorbid* or "multi morbid*") W3 (index* or indice* or measure* or rating* or scale* or score* or scoring*) 3401
S2 "Cumulative Illness Rating Scale" or (CIRS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 184
S3 "kaplan feinstein index" or (KFI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 6
S4 "charlson comorbidity index" or "Charlson Index" or (CCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 1710
S5 "Deyo Charlson Comorbidity Index" or "Deyo charlson index" or (DCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))
or (DCCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))
63
S6 "Charlson deyo comorbidity index" or "Charlson deyo index" or (CDI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))
or (CDCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*"))
145
S7 "aggregated diagnosis group" or (ADG and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 6
S8 "adjusted clinical groups" or (ACG and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 55
S9 "chronic disease score" or (CDS and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 79
S10 "index of coexistent disease" or (ICED and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 9
S11 "satariano index" 0
S12 "total illness burden index" or (TIBI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 5
S13 "Elixhauser comorbidity index" or "Elixhauser index" 52
S14 "comprehensive prognostic index" or (CPI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 12
S15 "american society of anesthesiologists physical status" or (ASA and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 761
S16 “adult comorbidity evaluation 27” or (ACE-27 and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 31
S17 "simplified comorbidity index" or (SCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 240
S18 "multipurpose australian comorbidity scoring system" 69
S19 "national cancer institute comorbidity index" or (NCI and (comorbid* or "co morbid*" or multimorbid* or "multi morbid*")) 41
S20 mortality or death 328565
S21 "activit* of daily living" or "activit* of daily life" or "ADL" or "iADL" or "functional decline" or (disabil* W3 function) 35185
S22 S20 OR S21 361153
S23 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 4916
S24 S22 and S23 (Limiters e Language: English) 2013
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Supplementary Material 2. Risk of Bias Assessment Tool:
Newcastle-Ottawa Quality Assessment Scale for Cohort Study
Selection (S)
(1) Representativeness of the study cohort
a) recruiting participants consecutively *
b) recruiting participants by selection
c) no description
(2) Selection of the exclusion cohort
a) report key criteria for patients that are excluded from the
study *
b) no description
(3) Ascertainment of scoring system (how is the index scored)




(4) Comparability of cohorts on the basis of the design or analysis
a) index adjusts for age/sex *
b) index adjust for any additional factor (ie, disease severity) *
c) index do not adjust for anything
d) index do not report for adjustment
Outcome (O)
(5) Assessment of outcome (mortality or ADL dependency)
a) independent blind assessment (reporting type of mortality
in the context of blind assessment) *
b) record linkage (ie, all-cause mortality) *
c) self-report (ie, follow-up interview for ADL dependency)
d) no description
(6) Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow up period for outcome of
interest) *
b) no
(7) Adequacy of follow-up of cohorts
a) complete follow-up: all subjects accounted for *
b) small number lost - >20 % *
c) follow-up rate <20% or no description of those lost
d) no statement
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Supplementary Fig. 1. Publication Bias.
Supplementary Table 1
Risk of Bias for Individual Articles
Author (year) S C O Total Stars
1 2 3 4 5 6 7
Arminanzas (2013)16 * * * * 4/8
Barba (2011)17 * * * * * * 6/8
Beglinger (2015)18 * * * * * 5/8
Bellelli (2008)43 * * * * * * 6/8
Beloosesky (2011)32 * * ** * 5/8
Bernard (2016)44 * * * * * * 6/8
Bien (2015)33 * * ** * * * 7/8
Buurman (2011)19 * * ** * * * 7/8
Conde-Martel (2012)20 * * ** * * * 7/8
D’Hoore (1993)47 * * * * * * 6/8
Dias (2015)21 * * * * * * 6/8
Duque (2011)22 * * * * * * 6/8
Fabbian (2017)23 * * * * * 5/8
Frenkel (2014)24 * * ** * * * 7/8
Helvik (2013)25 * * * * * * 6/8
Hernandez-Luiz (2018)26 * * ** * * * 7/8
Incalzi (1997)27 * * * * * * * 7/8
Iwata (2006)28 * * ** * * * 7/8
Martinez-Velilla (2014)34 * * * 3/8
Martinez-Velilla (2013)35 * * 2/8
Moore (2017)48 * * * * * * 6/8
Olsson (2005)29 * * * * 4/8
Quan (2011)49 * * * * * * 6/8
Ritt (2017)36 * * * ** * * * 8/8
Rozzini (2002)45 * * * ** * * * 8/8
Rozzini (2005)46 * * ** * * * 7/8
Salvi (2008)30 * * * * * 5/8
Tal (2011)31 * * * * * 5/8
Zekry (2009)37 * * * * 4/8
Zekry (2010)38 * * * * * 5/8
Zekry (2010)39 * * * * * 5/8
Zekry (2011)40 * * * * * 5/8
Zekry (2012)41 * * * * * 5/8
Zekry (2012)42 * * * * 4/8
C, comparability; O, outcome; S, selection.
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Supplementary Table 2
Proportion of Articles Reporting a Significant Association of Morbidity Measures and Mortality According to Morbidity Scores and Follow-Up Period
FU Score
CCI CIRS GIC ICED CDS



































































































































































































































































C, continuous; CDS, chronic disease score; FU, follow-up period; IH, inhospital. Portions indicate the number of articles reporting significant results out of the total number of
articles.
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